TG Therapeutics Inc. Stock
TG Therapeutics Inc. Stock
We can see a decrease in the price for TG Therapeutics Inc.. Compared to yesterday it has lost -€0.800 (-2.700%).
Currently there is a rather positive sentiment for TG Therapeutics Inc. with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 44 € shows a very positive potential of 52.78% compared to the current price of 28.8 € for TG Therapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for TG Therapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of TG Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of TG Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| TG Therapeutics Inc. | -2.700% | -1.014% | 22.762% | -11.001% | 10.791% | 57.549% | -21.824% |
| Heron Therapeutics Inc. | -0.410% | 10.879% | -0.581% | -54.196% | -30.925% | -70.630% | -94.480% |
| Evolus Inc | -0.770% | 2.890% | -17.972% | -56.585% | -34.679% | -52.848% | -62.723% |
| Sangamo Therapeutics Inc. | 1.000% | -15.105% | -33.193% | -65.067% | -36.535% | -85.093% | -97.648% |
Comments
TG Therapeutics (NASDAQ:TGTX) had its price target lowered by analysts at JPMorgan Chase & Co. from $49.00 to $46.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TGTX provided by MarketBeat
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for TGTX provided by MarketBeat
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TGTX provided by MarketBeat